Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors

Mayur Garg; Simon G. Royce; John S. Lubel

doi:10.1111/apt.15814

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors

Mayur Garg, Simon G. Royce, John S. Lubel

Research output: Contribution to journal › Letter › Other › peer-review

11 Citations (Scopus)

Abstract

We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].

Original language	English
Pages (from-to)	569-570
Number of pages	2
Journal	Alimentary Pharmacology & Therapeutics
Volume	52
Issue number	3
DOIs	https://doi.org/10.1111/apt.15814
Publication status	Published - Aug 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/apt.15814

Cite this

@article{2f110f52e6d7494cb64c9fde19e2e024,

title = "Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors",

abstract = "We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].",

author = "Mayur Garg and Royce, {Simon G.} and Lubel, {John S.}",

year = "2020",

month = aug,

doi = "10.1111/apt.15814",

language = "English",

volume = "52",

pages = "569--570",

journal = "Alimentary Pharmacology & Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Letter

T2 - intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors

AU - Garg, Mayur

AU - Royce, Simon G.

AU - Lubel, John S.

PY - 2020/8

Y1 - 2020/8

N2 - We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].

AB - We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].

UR - http://www.scopus.com/inward/record.url?scp=85084616470&partnerID=8YFLogxK

U2 - 10.1111/apt.15814

DO - 10.1111/apt.15814

M3 - Letter

C2 - 32374032

AN - SCOPUS:85084616470

VL - 52

SP - 569

EP - 570

JO - Alimentary Pharmacology & Therapeutics

JF - Alimentary Pharmacology & Therapeutics

SN - 0269-2813

IS - 3

ER -

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors

Abstract

UN SDGs

Access to Document

Other files and links

The Renin Angiotensin System in Inflammatory Bowel Disease

Cite this

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors

Abstract

UN SDGs

Access to Document

Other files and links

Projects

The Renin Angiotensin System in Inflammatory Bowel Disease

Cite this